Patel Jeegar Pravinkumar 4

What Happened

• Jeegar Pravinkumar Patel, Chief Scientific Officer of Evommune, exercised 13,512 option shares on June 1, 2026 at $3.84 per share (cost $51,886) and the filing also shows a derivative disposition of 13,512 shares at $0.00. On the same day he sold 16,687 shares in the open market for a weighted average price of $22.74, generating approximately $379,462. The sale was executed under a Rule 10b5-1 trading plan.

Key Details

• Transaction date: 2026-06-01 (reported on Form 4 filed 2026-06-03)
• Option exercise: 13,512 shares acquired at $3.84 each (total reported cost $51,886)
• Derivative disposition: 13,512 shares reported disposed at $0.00 (listed as a derivative transaction)
• Open-market sale: 16,687 shares sold at a weighted avg price of $22.74 (range $22.50–$23.35) for ~$379,462
• Plan/authorization: Transactions pursuant to a Rule 10b5-1 plan adopted Feb 27, 2026 (Footnote F1)
• Vesting: Option award vests 25% after one year, then monthly over 36 months (Footnote F3)
• Shares owned after the transaction: not disclosed in the provided filing
• Filing timeliness: Form 4 filed within typical SEC timing (no late-filing indication)

Context

• The filing shows an option exercise and a same-day market sale, which can be a standard way for insiders to exercise options and monetize gains. The separate derivative line at $0.00 likely relates to the mechanics of the option exercise/settlement (see Footnote F2 for sale price breakdown). These entries reflect executed transactions and not commentary on future company prospects; purchases generally carry more positive informational weight, while routine exercises and planned sales are common for insiders.